Literature DB >> 33070141

Transarterial Embolization in the Management of Intractable Haemorrhage.

Evi Comploj1,2, Alexander Pycha3, Emanuela Trenti4, Salvatore Palermo4, Matteo Bonatti5, Philipp Krause4, Decio Maria Folchini4, Armin Pycha4,6.   

Abstract

INTRODUCTION: The purpose of this study was to evaluate the effectiveness and long-term results of selective transarterial iliac embolization (STIE) in patients with intractable bladder haemorrhage (IBH).
METHODS: Twenty-five patients with a median age of 84 (range 65-94) years underwent STIE because of IBH between 2002 and 2020. The median follow-up time was 3 (mean 13.9) months. Patients were treated because of bleeding bladder or prostate cancer, radiation-induced haemorrhagic cystitis, and other conditions. Success was defined as technical success (feasibility to embolize bilateral hypogastric arteries or neoplastic arteries) and as clinical success (absence of further or additional therapy).
RESULTS: Twenty-five patients with a median age of 84 years with a median hospital stay of 7 days were embolized at our institution. In total, 60% required additional therapy. Only 20% had minor complications, but no complication major was seen; 60% needed an additional therapy because of continuous bleeding. Our 30-day, 90-day, 6-month, and 12-month mortality rates were 28, 44, 64, and 76%, respectively.
CONCLUSIONS: STIE in IBH is a safe, well-tolerated, and feasible procedure for palliating haematuria patients in poor general condition. Major complications are very rarely seen. However, patients often need additional therapy after STIE.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Bladder haemorrhage; Embolization; Haematuria; Internal iliac artery; Selective transarterial embolization

Mesh:

Year:  2020        PMID: 33070141     DOI: 10.1159/000511123

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  1 in total

1.  Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer.

Authors:  Bing Yuan; Hainan Xin; Jin Xin Fu; Mao Qiang Wang; Jin Long Zhang; Feng Duan; Hui Yi Ye; Hong Kai Yu; Dui-Ping Feng; Kai Cheng; Xiu Jun Zhang
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-05       Impact factor: 5.554

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.